New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data related to aficamten were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions held in collaboration with the American Heart Association Scientific Sessions 2026 in Chicago, IL including two late-breaking oral abstracts with additional data from ACACIA-HCM, and one poster presentation with new data from FOREST-HCM.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.